arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BioRestorative Therapies, Inc.

BRTX
$1.51 ▲ +0.01 (+0.33%) at close
Healthcare ·Services-Misc Health & Allied Services, NEC ·USServices-Misc Health & Allied Services, NEC
65 Visible periods
27 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, BioRestorative Therapies, Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $26.8M
Dividend Yield —
Revenue Growth -7.3% ↗
Op. Margin —
ROIC -88.4% ↗
FCF / Share $-0.21
Trailing P/E —
Price / Book 12.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$23.17K
↓ -7.3% —
Net Income Profit after all expenses
$-2.15M
↑ +59.7% —
FCF / Share Free cash flow per share
$-0.21
↑ +36.2% —
Long-Term Debt Long-term obligations
$10.29M
↑ +7.5% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -3465.0% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.77x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality ↑
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 65 quarters